The Head of GEROPHARM Group Petr Rodionov took part in the joint
meeting of the RSPP Commission on Health Industry, the RSPP Commission
on Pharmaceutical and Medical Industry and the CCI Committee for
Entrepreneurship in Healthcare and Medical Industry related to the
development of drugs and medical products production. The event was held
on April 18 in Moscow.
The Deputy Director of the Department of Pharmaceutical and Medical
Industry of the Ministry of Industry and Trade D. Kolobov, the Deputy
Director of the Contract System Development Department of the Ministry
of Economic Development D. Gotovtsev, the Chairman of the RSPP
Commission on the Pharmaceutical and Medical Industry Y. Kalinin, the
Chairman of the RSPP Commission on Health Industry V. Cherepov and the
Chairman of the CCI Committee for Entrepreneurship in Healthcare and
Medical Industry V. Sergienko, as well as the representatives of the
leading companies-manufacturers of drug products participated in the
The creation of full cycle productions in Russia was the most important
topic for discussion. The Head of GEROPHARM Group Petr Rodionov
stressed once again that today it is not reasonable to discuss the
issues connected with the capacities necessary for the production of
finished dosage forms of insulin, as there is a surplus of such products
in Russia and they can not affect the current state of the industry.
Therefore, speaking about full cycle insulin production, it is necessary
to keep in mind the production of the substance.
Petr Rodionov also shared information about the terms of bringing new
drug products to the market and the company's plans for the production
capacities expansion, which will help the company to cover 100% of the
Russian demand for genetically engineered and analogue insulins. He
emphasized that for the further development of insulin production in
Russia, the part of currently discussed support measures can be
considered very effective, for example, preferences, depending on the
depth of localization, and the mechanism of special investment contracts
conclusion with the possibility of obtaining the status of a sole
supplier. However, some initiatives, in particular, the procurement
centralization at the Federal level carries significant risks, like
supply disruptions, which for the patients with diabetics can be a
matter of life and death.
Among the most important issues, mentioned by the Head of GEROPHARM,
was the topic related to the violation of the legislation on public
procurement - when the procurement is conducted by trademarks but not by
INN, as it is prescribed in the Federal law 44 "On thecontract system".
The existence of similar problems was also confirmed by other
In conclusion, the participants agreed that today there are enough capacities for full cycle insulin production in Russia and there is a potential for providing the country with necessary drugs.The outcome of the meeting was the decision to support the projects, presented by the RSPP, and their consideration in the federal executive bodies.